Cargando…
PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis
BACKGROUND: Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is the most frequent subtype of secondary HLH triggered by infections. Previous studies have shown that ~30 % or more of patients with EBV-HLH do not respond to standard therapy. This study investigated the effica...
Autores principales: | Wang, Jingshi, Wang, Yini, Wu, Lin, Zhang, Jia, Lai, Wenyuan, Wang, Zhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017041/ https://www.ncbi.nlm.nih.gov/pubmed/27613189 http://dx.doi.org/10.1186/s13045-016-0317-7 |
Ejemplares similares
-
Chronic active Epstein-Barr virus infection treated with PEG-aspargase: A case report
por: Song, De-Li, et al.
Publicado: (2021) -
HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center
por: Song, Yue, et al.
Publicado: (2020) -
Epstein–Barr Virus and Hemophagocytic Lymphohistiocytosis
por: Marsh, Rebecca A.
Publicado: (2018) -
Epstein-Barr Virus-Induced Hemophagocytic Lymphohistiocytosis
por: Goudarzipour, K., et al.
Publicado: (2013) -
Development of a Nomogram to Predict the Risk of Chronic Active Epstein-Barr Virus Infection Progressing to Hemophagocytic Lymphohistiocytosis
por: He, Xiaodan, et al.
Publicado: (2022)